Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.63), $0.92 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $56.8 million versus the consensus estimate of $59.29 million.

In September 2023, Revance revised its 2023 GAAP and Non-GAAP operating expense guidance to reflect the company\'s exit of the OPUL payments business. Revance expects its 2023 GAAP operating expenses to be $545 million to $585 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation and amortization, stock-based compensation, and restructuring and impairment charges to be $315 million to $335 million. Revance expects its 2023 non-GAAP research and development expense to be $75 million to $85 million. The company’s non-GAAP operating expense guidance for 2023 primarily reflects increased investments in its aesthetics commercial infrastructure, including sales team expansion, and DAXXIFY and RHA Collection commercial investments.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.